​Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

​The purpose of this study is to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when compared to a placebo.

Principal Investigator: Dr. Geetha Maddukuri
Study Coordinator: Linda Schimmoeller

These studies are now closed to enrollment and data analysis has begun.

This study is funded through the Foundation and sponsored by Bayer.